Open AccessInvestigation of the effect of brexpiprazole on acute or relapse schizophrenia using the positive and negative syndrome scale: an experimental report
Author(s) -
哲朗 石田,
Tomonori Murayama
Publication year - 2022
Publication title -
brazilian journal of case reports
Language(s) - English
Resource type - Journals
ISSN - 2763-583X
DOI - 10.52600/2763-583x.bjcr.2022.2.1.83-89
Subject(s) - positive and negative syndrome scale , schizophrenia (object oriented programming) , psychopathology , negative symptom , medicine , psychiatry , antipsychotic , antipsychotic drug , psychosis , psychology , scale for the assessment of negative symptoms , clinical psychology
Brexpiprazole (BPZ) is a novel antipsychotic drug in the category of serotonin-dopamine activity modulators (SDAMs). It is expected to be effective in the treatment of schizophrenia because of its low side effects and its ability to reduce psychosis. However, clinical data in Japan are still insufficient. We prescribed BPZ to 41 schizophrenic patients; 9 of the 41 dropped out and 32 were retrospectively reviewed for psychiatric symptoms using the positive and negative syndrome scale (PANSS). The results showed that there was significant improvement in the total score, the positive scale, the negative scale and the general psychopathology scale, all after 4 weeks. The improvement started after 1 week for the total score, the positive scale and the general psychopathology scale, and after 2 weeks for the negative scale. The results suggest that BPZ is effective not only for positive symptoms in the acute phase, but also for negative symptoms after the subacute phase. Further studies are needed to investigate the efficacy of BPZ by patient's characteristics as well as by sub-items of the PANSS.